This press release is issued solely to correct a date from an AIM press release dated February 11, 2026. The Subscription Rights will expire if they are not exercised by 5:00 p.m., Eastern Time, on February 27, 2026, the expected expiration date of the Rights Offering. OCALA, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatoli ...

Core Viewpoint - AIM ImmunoTech Inc. has initiated a rights offering to raise funds for the development of its lead product, Ampligen® (rintatolimod), aimed at treating late-stage pancreatic cancer, a significant global health issue [1][10] Rights Offering Details - The rights offering allows holders of the Company's common stock and certain options and warrants to purchase up to 12,000 units at a subscription price of $1,000 per unit [2][4] - Each subscription right entitles the holder to purchase one unit, which consists of one share of Series G Convertible Preferred Stock and 1,666 warrants to purchase common stock [3] - The preferred stock is convertible into 833 shares of common stock at a conversion price of $1.20 per share, and each warrant is exercisable for one share of common stock at the same exercise price [3] Financial Projections - If fully subscribed, the rights offering is expected to generate gross proceeds of $12 million [4] - Holders who fully exercise their basic subscription rights can subscribe for additional units that remain unsubscribed [4] Subscription Period - The subscription period commenced on February 11, 2026, and will end on February 27, 2026, unless extended by the Company [5] - Subscription rights are non-transferable and must be exercised during the subscription period [5] Management and Regulatory Information - Maxim Group LLC has been engaged as the dealer-manager for the rights offering [6] - The offering is made pursuant to a registration statement declared effective by the SEC on February 10, 2026 [7]

Core Viewpoint - Signing Day Sports, Inc. has successfully closed a public offering of 9,483,500 shares of common stock, along with warrants to purchase an additional 14,225,250 shares, at a price of $0.5905 per share [1] Group 1: Offering Details - The warrants are initially exercisable at a price of $0.7086 per share, with a zero cash exercise option available until January 23, 2026, subject to a floor price of $0.6760 per share [2] - Gross proceeds from the offering, before deducting underwriting discounts and commissions, were approximately $5.6 million [3] - The offering was managed by Maxim Group LLC as the sole book-running manager [3] Group 2: Regulatory Information - A registration statement on Form S-1 was filed with the U.S. Securities and Exchange Commission (SEC) and declared effective on January 13, 2026 [4] - A final prospectus related to the offering has been filed with the SEC and is available on their website [4] Group 3: Company Overview - Signing Day Sports aims to assist student-athletes in the recruitment process for college sports through its app, which allows users to create recruitment profiles with video-verified measurables and academic information [6]

Core Viewpoint - Signing Day Sports, Inc. has successfully closed a public offering of 9,483,500 shares of common stock at a price of $0.5905 per share, along with warrants to purchase an additional 14,225,250 shares [1][3] Group 1: Offering Details - The warrants are initially exercisable at $0.7086 per share and can be exercised on a zero cash basis, subject to a floor price of $0.6760 per share until January 23, 2026 [2] - The gross proceeds from the offering, before deducting underwriting discounts and commissions, were approximately $5.6 million [3] - The offering was conducted under a registration statement that was declared effective by the SEC on January 13, 2026 [4] Group 2: Company Overview - Signing Day Sports aims to assist student-athletes in the recruitment process for college sports through its app, which allows users to create recruitment profiles with video-verified measurables and academic information [6]

As filed with the Securities and Exchange Commission on January 12, 2026. Registration No. 333-292569 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Signing Day Sports, Inc. (Exact name of registrant as specified in its charter) Delaware 7389 87-2792157 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identificati ...

As filed with the U.S. Securities and Exchange Commission on December 31, 2025. Registration No. 333-292077 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to Form F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Rubico Inc. (Exact name of Registrant as specified in its charter) Republic of the Marshall Islands (State or other jurisdiction of incorporation or organization) 4412 (Primary Standard Industrial Classification Code Number) N/A (I.R.S. Employer Id ...

Core Viewpoint - Titan Mining Corporation is accelerating its development to become the first end-to-end natural flake graphite producer in the U.S. in 70 years, supported by a US$15 million investment from a leading institutional equity investor [1][4]. Investment Details - The investment will be executed through a private placement of 6,666,666 special warrants at a price of US$2.25/C$3.10 per warrant [4][9]. - This funding, along with US$5.5 million from the U.S. EXIM Bank, positions Titan to expedite the completion of the Kilbourne Graphite Feasibility Study in 2026 and move towards construction [2][9]. Strategic Importance - The investment is seen as a strong endorsement of Titan's strategy to re-establish a domestic graphite supply chain, enhancing U.S. critical minerals security [4][8]. - Titan aims to deliver shareholder value through operational excellence and the development of critical minerals assets [8]. Warrant Structure - The warrants will be exercisable in two tranches, with 50% at a 35% premium and the remaining 50% at a 65% premium to the issue price [5][9]. - The company has the option to call the warrants if its common shares trade above 150% of the exercise price for 15 trading days within any 30-day period [6][9].

Core Insights - Medicus Pharma Ltd. has entered into a warrant inducement agreement for the immediate exercise of all outstanding Series A and Series B Warrants issued on July 14, 2025 [1] Company Summary - Medicus Pharma Ltd. is a precision guided biotech/life sciences company focused on advancing clinical development programs of novel and potentially disruptive therapeutic assets [1] Transaction Details - Maxim Group LLC is acting as the exclusive Financial Advisor for the transaction [1]

As filed with the Securities and Exchange Commission on December 1, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Jet.AI Inc. (Exact name of registrant as specified in its charter.) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Number) Delaware 4522 93-2971741 (IRS Employer Identification No.) 10845 Griffith Peak Dr. Suite 200 Las ...

Core Points - VisionSys AI Inc. has entered into securities purchase agreements for the sale of 9,230,750 American Depositary Shares (ADS) and warrants at a combined offering price of $1.30 per ADS and accompanying warrants [1][3] - The gross proceeds from the offering are estimated to be approximately $12.0 million before deducting fees and expenses, with the offering expected to close on or about November 13, 2025 [3] - The warrants are immediately exercisable and will expire five years from issuance, with an initial exercise price of $1.30 per ADS, subject to adjustments [2] Company Overview - VisionSys AI Inc. specializes in brain-machine interaction businesses, leveraging core algorithms and related software and hardware systems [6] - The company is focused on advancing AI-powered healthcare and biotech solutions, aiming to create a smarter, more connected future [6]